分析和公共政策:调和关于除虫的证据
Kevin Croke1, Joan Hamory2, Eric Hsu3
1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA 02115.
概括
针对肠的大规模药物管理 (MDA) 显著改善了儿童的体重,身高和手臂周长在高流行地区. 这种具有成本效益的干预措施符合世卫组织对公共卫生的建议.
科学领域:
- 公共卫生 公共卫生
- 传染性疾病 传染性疾病
- 全球健康 全球健康
背景情况:
- 世界卫生组织 (WHO) 建议在流行地区 (20%以上的流行率) 针对肠虫感染进行大规模药物管理 (MDA).
- 最近的元分析表明,个人治疗比MDA更好,因此需要进一步的证据.
- 肠道虫感染对公众健康构成重大挑战,特别是在儿童中.
研究的目的:
- 进行理论无关的元分析,评估多剂量MDA对儿童健康结果的影响.
- 为了进行MDA对肠道虫感染的成本效益分析.
- 评估MDA在感染率超过20%的地区的疗效.
主要方法:
- 对检查多剂量MDA干预措施的研究进行了随机效应元分析.
- 综合了成本效益分析,以评估干预措施的经济可行性.
- 分析了数据对儿童体重,中高臂周长,身高和血红蛋白 (Hb) 水平的影响.
主要成果:
- 在患病率>20%的地区,MDA对儿童体重 (0.15公斤),中臂周长 (0.20厘米) 和身高 (0.09厘米) 产生了显著的积极影响.
- 没有观察到对血红蛋白 (Hb) 水平 (0.06 g/dL) 的显著影响.
- 分析表明,在推的设置中,MDA是一种具有成本效益的策略.
结论:
- 多剂量大规模药物管理是一种有效的干预措施,用于改善高流行地区儿童的关键人体测量指标.
- 医疗补助是一个具有成本效益的公共卫生战略,特别是在世卫组织指导方针建议实施的地方.
- 可能需要进一步的研究来探索对微量营养素状况的影响,如Hb.
更多相关视频
相关概念视频
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Drug Control Governance: Regulatory Bodies and Their Impact
153
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
153
Dose-Response Relationship: Potency and Efficacy
4.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.4K


